Insmed to Host Analyst and Investor Day on July 19, 2017
July 12 2017 - 8:00AM
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical
company focused on the unmet needs of patients with rare diseases,
announced today that it will host an Analyst and Investor Day on
Wednesday, July 19, 2017. The event is scheduled to take place from
8:30-11:45 AM Eastern Time in New York City, NY.
The agenda will include an overview of the Company’s development
and pre-commercial plans for Amikacin Liposome Inhalation
Suspension (ALIS), as well as an introduction to the Company’s
Phase 2 candidate INS1007.
The program will also feature a presentation by Dr. Kevin L.
Winthrop, MD, MPH, Professor at the School of Public Health, and
Associate Professor in the Departments of Infectious Diseases and
Ophthalmology at Oregon Health & Science University.
The event will be webcast live and can be accessed by visiting
the investor relations section of the company’s website at
www.insmed.com. The webcast will be archived for a period of 90
days following the conclusion of the live event.
About Insmed
Insmed Incorporated is a global biopharmaceutical company
focused on the unmet needs of patients with rare diseases. The
company is advancing a global phase 3 clinical study of ARIKAYCE®
(Amikacin Liposome Inhalation Suspension) for adult patients with
treatment refractory nontuberculous mycobacteria (NTM) lung disease
caused by Mycobacterium avium complex (MAC), which is a rare and
often chronic infection that is capable of causing irreversible
lung damage and can be fatal. There are currently no approved
inhaled products specifically indicated for the treatment of
refractory NTM lung disease caused by MAC in the United States or
the European Union. Insmed's earlier-stage clinical pipeline
includes INS1007, a novel oral reversible inhibitor of DPP1 with
therapeutic potential in non-cystic fibrosis bronchiectasis, and
INS1009, an inhaled nanoparticle formulation of a treprostinil
prodrug that may offer a differentiated product profile for rare
pulmonary disorders, including pulmonary arterial hypertension. For
more information, visit www.insmed.com.
"Insmed" and "ARIKAYCE" are the company's trademarks. All other
trademarks, trade names or service marks appearing in this press
release are the property of their respective owners.
Investor Contact:
Laura Perry or Heather Savelle
Argot Partners
212-600-1902
laura@argotpartners.com
heather@argotpartners.com
Insmed (NASDAQ:INSM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Insmed (NASDAQ:INSM)
Historical Stock Chart
From Sep 2023 to Sep 2024